For the year ending 2025-12-31, CTMX had -$24,885K decrease in cash & cash equivalents over the period. -$75,807K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -17,368 |
| Amortization of intangible assets | 146 |
| Depreciation and amortization | 1,230 |
| Impairment loss on machinery and equipment | -402 |
| Accretion of discounts on short-term investments | 2,206 |
| Stock-based compensation expense | 6,302 |
| Non-cash lease expense | -4,483 |
| Accounts receivable | -1,090 |
| Prepaid expenses and other assets | 1,242 |
| Accounts payable | 221 |
| Accrued liabilities and other long-term liabilities | -3,049 |
| Deferred revenue | -65,596 |
| Net cash used in operating activities | -75,587 |
| Purchases of property and equipment | 220 |
| Purchases of short term investments | 192,524 |
| Maturities of short term investments | 133,000 |
| Net cash provided by (used in) investing activities | -59,744 |
| Proceeds from issuance of pre-funded warrants and warrants, net of issuance cost | 0 |
| Proceeds from issuance of common stock, net of issuance cost | 109,635 |
| Proceeds from employee stock purchase plan and exercise of stock options | 811 |
| Net cash provided by financing activities | 110,446 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -24,885 |
| Cash, cash equivalents and restricted cash, beginning of year | 39,079 |
| Cash, cash equivalents and restricted cash, end of year | 14,194 |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)